Semorinemab - AC Immune/Genentech
Alternative Names: anti-tau monoclonal antibody - AC Immune/Genentech; MTAU-9937A; RG-6100; RO 7105705Latest Information Update: 24 Apr 2025
At a glance
- Originator AC Immune
- Developer Chugai Pharmaceutical; Genentech; Roche
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 31 Dec 2024 AC Immune terminated collaboration agreement with Genentech, a member of the Roche Group
- 19 Feb 2024 Discontinued - Phase-I for Alzheimer's disease in USA (SC)
- 15 Feb 2024 Discontinued - Phase-II for Alzheimer's disease in USA, France, Australia, United Kingdom, Italy, Sweden, Germany, Denmark, Poland, Netherlands, Canada, Belgium, Spain (IV) (Roche pipeline, February 2024)